Aditxt Files Pro Forma Financials for Ignite Proteomics Acquisition Valued at $36M in Preferred Stock
ADTX is trading near its 52-week low of $0.5 (3.9% above the low).
Summary
Aditxt filed pro forma financials for its $36 million acquisition of Ignite Proteomics LLC, a loss-making entity, significantly expanding its balance sheet and increasing losses amidst existing financial distress.
Key Events · M&A and Partnerships · ADTX
-
Acquisition Details Finalized
Aditxt completed the acquisition of Ignite Proteomics LLC on March 11, 2026, issuing 36,000 shares of Series A-2 Convertible Preferred Stock with a stated value of $36.0 million, plus assuming $0.8 million in operating liabilities.
-
Significant Financial Impact
The pro forma financials show the acquisition substantially increases Aditxt's total assets and significantly adds to its consolidated net losses, which are already substantial.
-
Acquired Entity's Distress
Ignite Proteomics LLC reported a "going concern" doubt, minimal revenues ($43,539 in 2025), and significant net losses ($5.7 million in 2025), including an impairment loss on its equipment.
-
Massive Goodwill Recognized
A preliminary goodwill of $36.551 million was recognized, indicating a substantial premium paid over the identifiable net tangible assets of the acquired, loss-making business.
Analysis · ADTX · Life Sciences
This 8-K/A provides the previously omitted financial statements and pro forma information for Aditxt's acquisition of Ignite Proteomics LLC, completed on March 11, 2026. The acquisition, valued at $36.0 million in Series A-2 Convertible Preferred Stock plus assumed operating liabilities, is extraordinarily large relative to Aditxt's current operational scale. Ignite Proteomics itself is a loss-making entity with a "going concern" doubt and minimal revenue, having also recorded an impairment loss on its equipment. This transaction significantly expands Aditxt's balance sheet and increases its consolidated losses, adding to the company's existing financial distress, which includes a "going concern" warning, Nasdaq delisting risk, and ongoing substantial dilution from an At-The-Market offering. The large goodwill component in the purchase price allocation further raises concerns about the value received.
At the time of this filing, ADTX was trading at $0.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $469.9K. The 52-week trading range was $0.50 to $4,962.92. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.